Press Release: Bio-Path Holdings Reports Full Year 2024 Financial Results

Dow Jones
Mar 28

Bio-Path Holdings Reports Full Year 2024 Financial Results

Reports Continued Progress Across Both Obesity and Oncology Franchises

HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize$(R)$ antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments.

"We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize(R) platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the body of scientific evidence in support of our powerful platform technologies' therapeutic effects and fortified our intellectual property to protect it from potential competitors. We continue to advance our clinical studies for BP1001-A as a treatment for obesity in Type 2 diabetes patients, where we have shown restored insulin sensitivity in cell models. Beyond this, our ongoing oncology studies continue to advance, and we are reporting ever improving outcomes for the most vulnerable patients battling these life-threatening cancers."

Recent Corporate Highlights

   -- Announced Pre-Clinical Results Signaling Increased Potential for BP1001-A 
      as Treatment for Obesity in Type 2 Diabetes Patients. Scientific evidence 
      suggests that by downregulating growth factor receptor-bound protein 2 
      (Grb2) expression, BP1001-A could help lower blood glucose level by 
      affecting insulin signaling. In December 2024, Bio-Path reported results 
      from preclinical studies of BP1001-A for obesity demonstrating enhanced 
      insulin sensitivity in myoblast and hepatoma cells. Furthermore, in March 
      2025, Bio-Path reported preclinical results that BP1001-A attenuated 
      fatty acid-induced insulin resistance and restored insulin sensitivity in 
      muscle progenitor and skeletal muscle fiber cell models. Together these 
      studies signal increased potential for BP1001-A as a treatment for 
      obesity and related metabolic diseases in Type 2 diabetes patients. 
   -- Expanded Global Patent Portfolio. In February 2025, Bio-Path announced 
      the receipt of newly issued patents in the United States and New Zealand, 
      and updated investors on the extent of its global intellectual property 
      portfolio. Bio-Path received Notice of Allowance from the United States 
      Patent and Trademark Office for U.S. Patent No. 17/339,366 titled, 
      "P-ethoxy nucleic acids for STAT3 inhibition." The New Zealand 
      Intellectual Property Office has granted Patent No. 741793 titled, 
      "P-ethoxy nucleic acids for liposomal formulation." These new patents 
      build on earlier patents granted that protect the DNAbilize(R) platform 
      technology and the Company's novel RNAi nanoparticle drugs. 

Bio-Path continues to expand its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy. Bio-Path's patent portfolio currently includes seven issued patents in the U.S. and 61 issued patents in foreign jurisdictions, providing protection in 26 countries. The Company has three additional pending patent applications in the U.S. and five additional allowed patent applications in foreign jurisdictions.

   -- Provided Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of 
      Refractory/Relapsed Acute Myeloid Leukemia. In February 2025, the Company 
      provided an update from the ongoing Phase 1/1b clinical trial evaluating 
      BP1002 for the treatment of refractory/relapsed acute myeloid leukemia 
      $(AML.UK)$, including venetoclax-resistant patients. The Company announced a 
      meaningful patient response to treatment and that the study has 
      progressed to the fourth, higher dose cohort of 90 mg/m2. 

Financial Results for the Year Ended December 31, 2024

   -- The Company reported a net loss of $9.9 million, or $4.12 per share, for 
      the year ended December 31, 2024, compared to a net loss of $16.1 million, 
      or $33.63 per share, for the year ended December 31, 2023. 
   -- Research and development expense for the year ended December 31, 2024 
      decreased to $7.3 million, compared to $11.6 million for the year ended 
      December 31, 2023 primarily due to decreased manufacturing expenses 
      related to drug product releases in 2024 compared to 2023. 
   -- General and administrative expense for the year ended December 31, 2024 
      increased to $4.7 million, compared to $4.2 million for the year ended 
      December 31, 2023 primarily due to increased salaries and benefits 
      expense as well as expenses related to our special shareholder meeting in 
      2024. 
   -- Change in fair value of the Company's warrant liability for the year 
      ended December 31, 2024 resulted in a non-cash income of $2.1 million 
      compared to a non-cash loss of $0.3 million for the year ended December 
      31, 2023. 
   -- As of December 31, 2024, the Company had cash of $1.2 million, compared 
      to $1.1 million as of December 31, 2023. Net cash used in operating 
      activities for the year ended December 31, 2024 was $10.6 million 
      compared to $11.5 million for the comparable period in 2023. Net cash 
      provided by financing activities for the year ended December 31, 2024 was 
      $10.7 million. 

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize(R) , a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. BP1001-A is also being evaluated as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. The Company's second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at www.biopathholdings.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path's ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10-K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Investors

Will O'Connor

Stern Investor Relations, Inc.

212-362-1200

will@sternir.com

Doug Morris

Investor Relations

Bio-Path Holdings, Inc.

832-742-1369

(END) Dow Jones Newswires

March 28, 2025 07:00 ET (11:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10